OrthoPediatrics Corp. (NASDAQ:KIDS) Receives $26.44 Consensus Target Price from Brokerages

OrthoPediatrics Corp. (NASDAQ:KIDS) has been given a consensus rating of “Moderate Buy” by the eleven analysts that are covering the firm, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation, one has given a hold recommendation and nine have given a buy recommendation to the company. The average twelve-month target price among brokers that have updated their coverage on the stock in the last year is $26.4444.

Several research analysts recently weighed in on KIDS shares. Truist Financial set a $22.00 price target on shares of OrthoPediatrics in a report on Wednesday, August 5th. Piper Sandler reiterated an “overweight” rating and issued a $25.00 price objective (up from $22.00) on shares of OrthoPediatrics in a research note on Wednesday, August 5th. BTIG Research lifted their target price on shares of OrthoPediatrics from $24.00 to $29.00 and gave the stock a “buy” rating in a research report on Thursday, August 20th. Needham & Company LLC boosted their target price on OrthoPediatrics from $30.00 to $35.00 and gave the stock a “buy” rating in a research note on Wednesday, August 5th. Finally, Weiss Ratings raised OrthoPediatrics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Wednesday, August 5th.

Insider Buying and Selling

In other OrthoPediatrics news, Director David R. Pelizzon sold 10,131 shares of the business’s stock in a transaction on Tuesday, September 1st. The stock was sold at an average price of $23.10, for a total value of $234,026.10. Following the transaction, the director owned 6,526,633 shares of the company’s stock, valued at approximately $150,765,222.30. The trade was a 0.15% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, major shareholder Squadron Capital Llc sold 10,131 shares of the company’s stock in a transaction on Tuesday, September 1st. The shares were sold at an average price of $23.10, for a total value of $234,026.10. Following the completion of the transaction, the insider owned 6,526,633 shares of the company’s stock, valued at $150,765,222.30. This trade represents a 0.15% decrease in their position. The SEC filing for this sale provides additional information. Over the last three months, insiders have sold 1,125,393 shares of company stock worth $26,113,488. 32.50% of the stock is owned by company insiders.

Hedge Funds Weigh In On OrthoPediatrics

Institutional investors have recently added to or reduced their stakes in the stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in OrthoPediatrics by 6.9% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 9,995 shares of the company’s stock worth $246,000 after acquiring an additional 645 shares during the period. Millennium Management LLC grew its position in shares of OrthoPediatrics by 55.3% during the 1st quarter. Millennium Management LLC now owns 656,578 shares of the company’s stock valued at $16,172,000 after acquiring an additional 233,873 shares during the period. Goldman Sachs Group Inc. grew its position in shares of OrthoPediatrics by 112.3% during the 1st quarter. Goldman Sachs Group Inc. now owns 200,439 shares of the company’s stock valued at $4,937,000 after acquiring an additional 106,041 shares during the period. Jane Street Group LLC purchased a new stake in shares of OrthoPediatrics during the 1st quarter worth approximately $389,000. Finally, American Century Companies Inc. increased its stake in shares of OrthoPediatrics by 12.5% during the 2nd quarter. American Century Companies Inc. now owns 34,486 shares of the company’s stock worth $741,000 after purchasing an additional 3,828 shares during the last quarter. Institutional investors own 69.05% of the company’s stock.

Trending Headlines about OrthoPediatrics

Here are the key news stories impacting OrthoPediatrics this week:

• Positive Sentiment: Analysts assigned OrthoPediatrics a consensus price target of $26.44, implying potential upside from recent trading levels and signaling continued confidence in the company’s long-term growth prospects. OrthoPediatrics Receives $26.44 Consensus Price Target
• Neutral Sentiment: The reported sales appear across related director, major-shareholder and beneficial-ownership filings, meaning some transactions may represent overlapping disclosures rather than entirely separate blocks of stock. After the transactions, the reporting holders still controlled approximately 6.53 million shares, indicating continued substantial exposure to KIDS. SEC Insider Transaction Filing
• Negative Sentiment: Director David R. Pelizzon and major shareholder Jennifer N. Pritzker reported sales of 326,700 shares on August 28 at an average price of $23.04, worth approximately $7.53 million. Each reduced their reported ownership by 4.76%, which may pressure the stock or raise concerns about insider confidence, although both retained large positions. SEC Major Shareholder Ownership Filing
• Negative Sentiment: The same holders, along with Squadron Capital LLC, reported additional sales of 10,131 shares on September 1 at $23.10, worth approximately $234,000 per reported transaction. The small 0.15% ownership reduction is less significant by itself, but reinforces the near-term insider-selling overhang. SEC Ownership Filing

OrthoPediatrics Trading Down 1.3%

NASDAQ KIDS opened at $23.00 on Wednesday. The company has a current ratio of 4.78, a quick ratio of 2.17 and a debt-to-equity ratio of 0.28. The business has a fifty day simple moving average of $21.61 and a 200 day simple moving average of $18.76. OrthoPediatrics has a 12 month low of $14.42 and a 12 month high of $26.74. The firm has a market capitalization of $600.53 million, a P/E ratio of -13.69 and a beta of 0.98.

OrthoPediatrics (NASDAQ:KIDS) last posted its quarterly earnings data on Tuesday, August 4th. The company reported ($0.26) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.30) by $0.04. The firm had revenue of $70.51 million for the quarter, compared to the consensus estimate of $68.21 million. OrthoPediatrics had a negative net margin of 15.72% and a negative return on equity of 8.10%. On average, analysts predict that OrthoPediatrics will post -1.14 EPS for the current fiscal year.

About OrthoPediatrics

OrthoPediatrics Corp., founded in 2007 and headquartered in Warsaw, Indiana, is a medical device company dedicated exclusively to providing orthopedic solutions for children. The company focuses on developing, manufacturing and marketing a broad portfolio of implants and instruments designed to address a wide range of pediatric conditions, including trauma, deformity correction, spine disorders and sports injuries.

The company’s product lines include locking plates and screws for upper and lower extremity reconstruction, intramedullary nails for femur and tibia stabilization, and specialized systems such as the MAGEC Magnetic Growth Rod for treatment of early-onset scoliosis.